FDA Approves SetPoint Neuroimmune Modulation Device for Rheumatoid Arthritis
The FDA has approved the innovative SetPoint System, a neuroimmune device designed to activate the body's natural anti-inflammatory pathways for treating rheumatoid arthritis, offering hope for patients resistant to conventional therapies.
The U.S. Food and Drug Administration has granted approval for the SetPoint System, an innovative neuroimmune modulation device designed to treat adults suffering from moderate-to-severe rheumatoid arthritis (RA). This groundbreaking device is intended for individuals who do not experience adequate relief from or cannot tolerate existing advanced RA treatments, including biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs).
The SetPoint System is an implantable device that uniquely delivers electrical stimulation to the vagus nerve once daily. This stimulation aims to activate the body's natural anti-inflammatory and immune-restorative pathways, offering a new approach to managing autoimmune inflammation. The device's approval follows positive results from the RESET-RA clinical trial, which involved 242 participants randomly assigned to receive either the SetPoint Device or a sham device.
In the study, the primary goal was to achieve a 20% improvement according to the American College of Rheumatology criteria after three months. The trial successfully met this endpoint, with participants showing sustained improvements in response rates and disease activity over 12 months. Notably, about 75% of the patients managed to stay off biologic or targeted synthetic DMARDs after a year. The implantation procedure and subsequent stimulation were well tolerated, with a low side effect rate of 1.7% for serious adverse events.
According to Dr. Mark Richardson of Harvard University, who led the trial, the approval underscores the promising potential of neuroimmune modulation as a novel therapy for autoimmune diseases. After a minimally invasive outpatient procedure, the device is programmed to operate automatically on a set schedule, with a lifespan of up to 10 years, simplifying ongoing care for RA patients.
The SetPoint device has been approved for use by SetPoint Medical, marking a significant advancement in rheumatoid arthritis treatment options.
source: https://medicalxpress.com/news/2025-08-fda-setpoint-neuroimmune-modulation-device.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Genetic Variants as Key Factors in Diverse Clinical Outcomes of Complex Disorders
Emerging research reveals that secondary genetic variants significantly influence the clinical diversity seen in complex disorders, emphasizing the importance of genetic background and cohort selection in understanding disease variability.
New Algorithm Unveils the Brain's Small Region Critical for Motivation
Discover how a tiny brain area called the VTA encodes not only reward predictions but also their precise timing, revealing new insights into motivation and learning through advanced AI techniques.
Majority of Patients with Advanced Melanoma Remain Disease-Free Four Years Post-Neoadjuvant Immunotherapy
A groundbreaking study shows that nearly 87% of advanced melanoma patients remain disease-free four years after pre-surgical immunotherapy, highlighting the potential of neoadjuvant treatment to improve long-term outcomes.
More Americans Now Meet the Criteria for High Blood Pressure Under New Guidelines
Recent updates to blood pressure guidelines have expanded the number of Americans classified as hypertensive, emphasizing lifestyle changes, personalized risk assessment, and early intervention to prevent cardiovascular disease.